When Slowing Down Counts as Progress
A 48-week trial of AMX0035 in Wolfram syndrome patients showed stabilization of vision and improved pancreatic function in people whose disease typically strips away both, according to Phase 2 data published in The Journal of Clinical Investigation [2]. For a condition that begins in childhood with diabetes and progressive blindness, then layers on neurological symptoms with no approved treatments, the drug's ability to slow deterioration represents something rare disease communities seldom see: evidence that decline might not be inevitable.
Wolfram syndrome follows a visible trajectory. It starts with insulin-requiring diabetes and optic nerve degeneration affecting vision, typically in childhood, then adds broader neurological symptoms that increasingly interfere with daily life [2]. No disease-modifying treatments exist [2]. Patients know what's coming. The HELIOS trial enrolled people with "advanced disease course", participants at least 17 years old who had already lost years to the condition [2].
Over 48 weeks, AMX0035, an oral combination of sodium phenylbutyrate and taurursodiol [2], demonstrated continued improvements in pancreatic beta cell function, measured by C-peptide response to a mixed-meal tolerance test [2]. C-peptide indicates how much insulin the pancreas still produces; rising levels mean beta cells are working better. Secondary measures of glycemic control, including HbA1c and time in target glucose range between 70 and 180 mg/dL, improved from baseline at both 24 and 48 weeks [2]. Best-corrected visual acuity trended toward stabilization over the same period [2].
The objective measurements matter, but so does what participants reported in qualitative interviews: meaningful improvements in diabetes and vision problems [2]. When you've spent your life losing function piece by piece, stabilization registers as gain. The trial design reflects the constraints of rare disease research: single-site, single-arm, open-label, no control group [2]. That structure makes it impossible to separate drug effect from placebo response or natural disease variation, but assembling enough Wolfram patients for a randomized controlled trial raises its own ethical questions when no other treatment options exist.
The Evidence Standard for Diseases Without Options
Phase 2 data with this design would not typically reach publication in a journal like JCI for common conditions. The hierarchy of clinical evidence puts randomized, double-blind, placebo-controlled trials at the top. Open-label, single-arm studies sit several rungs lower. But Wolfram syndrome affects roughly one in 500,000 people. Waiting for perfect data means patients die waiting. The rare disease pathway operates under different rules because the alternative is no data at all.
Amylyx Pharmaceuticals continues to work with the FDA on a Phase 3 trial design [2]. That negotiation is ongoing, meaning regulatory clarity comes after publication. The company withdrew its ALS drug Relyvrio in 2024 after it failed Phase 3 confirmation, making the gap between Phase 2 results and Phase 3 validation more than theoretical for patients watching this data. Publication in a peer-reviewed journal gives the findings scientific legitimacy but not regulatory approval. The drug remains investigational.
The safety profile showed no serious adverse events related to AMX0035 treatment, with reported effects classified as mild or moderate [2]. That tolerability matters for a chronic condition requiring long-term dosing, but the 48-week window captures only part of what patients need to know about taking a drug for years or decades. Phase 3 will need to answer duration questions that Phase 2 cannot.
What Stabilization Means When You're Already Behind
The trial measured outcomes at 24 and 48 weeks [2], a timeframe that shows direction but not durability. Wolfram syndrome progresses over years. Whether AMX0035 can hold the line beyond 48 weeks, or whether the stabilization represents a temporary plateau before decline resumes, requires longer observation. The qualitative interviews captured what participants felt during the trial period, but feelings are not a substitute for the functional measures that determine whether someone can work, drive, or manage their own insulin.
Fumihiko Urano, the principal investigator and Samuel E. Schechter Professor of Medicine at Washington University School of Medicine in St. Louis [2], led the trial at a single site. Concentrating expertise makes sense for rare diseases, but it also means the results reflect one center's patient population and one team's treatment protocols. Replication across sites would strengthen confidence that the effects generalize.
The publication arrives as Amylyx negotiates Phase 3 design with the FDA [2]. That negotiation will determine what endpoints regulators consider sufficient for approval, how long the trial must run, and whether a control arm is feasible or ethical given the lack of alternative treatments. The company's history with Relyvrio, accelerated approval followed by voluntary withdrawal after confirmatory trial failure, shapes how both regulators and patients interpret preliminary data. Phase 2 results do not predict Phase 3 outcomes.
For Wolfram patients, the calculus is not whether the data is perfect. It is how many more years of function they will lose while waiting for certainty. The disease does not pause for clinical trial timelines. Every month of delayed vision stabilization is vision that does not come back. Every period of uncontrolled diabetes is cumulative damage to organs and nerves. The question is not whether AMX0035 meets the evidentiary standard for common diseases with multiple treatment options. The question is what standard applies when the alternative is watching deterioration with no tools to slow it, and whether 48 weeks of stabilization in people with advanced disease justifies the risk of hoping it continues.
